Latest news
FDA Accepts daraxonrasib Application for RAS-Mutant Pancreatic Cancer - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTFDA Grants Breakthrough Therapy Designation to Olomorasib for KRAS G12C-Mutant Advanced Pancreatic Cancer - OncodailyOncodaily · Wed, 05 Aug 2026 13:26:29 GMTPancreatic Cancer Vaccine Shows Interception Promise in High-Risk Patients - MedPage TodayMedPage Today · Tue, 04 Aug 2026 21:08:29 GMTOlomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer - CancerNetworkCancerNetwork · Tue, 04 Aug 2026 15:38:44 GMTSilexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock TitanStock Titan · Tue, 04 Aug 2026 13:15:00 GMTLilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer - PMLiVEPMLiVE · Tue, 04 Aug 2026 10:55:00 GMTFDA Grants Breakthrough Status to Olomorasib in Pancreatic Cancer - targetedonc.comtargetedonc.com · Mon, 03 Aug 2026 20:07:34 GMTLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - PR NewswirePR Newswire · Mon, 03 Aug 2026 11:45:00 GMT